Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Authors:
- 3 October 2018
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 14 (7) , 715-724
Abstract
Background: R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer. More chemotypes of inhibitors of IDH1(R132H) are therefore needed. Objective: The study aimed to develop a new class of IDH1(R132H) inhibitors as potent antitumor agents. Method: A biochemical assay was developed to find inhibitors of IDH1(R132H) mutant enzyme. Chemical synthesis and structure-activity relationship studies were used to find compounds with improved potency. Antitumor activities of selected compounds were evaluated. Results: A series of aromatic sulfonamide compounds was found to be novel, potent inhibitors of IDH1(R132H) with Ki values as low as 0.6 µM. Structure-activity relationships of these compounds are discussed. Enzyme kinetics studies showed that one compound is a competitive inhibitor against the substrate α-KG and a non-competitive inhibitor against the cofactor NADPH. Several inhibitors were found to have no activity against wild-type IDH1, showing a high selectivity. Two potent inhibitors exhibited strong activity against proliferation of BT142 glioma cells with IDH1 R132H mutation, while these compounds did not significantly affect the growth of glioma cells without IDH1 mutation. Conclusion: This novel series of IDH1(R132H) inhibitors have potential to be further developed for the treatment of glioma with IDH1 mutation.Keywords
This publication has 17 references indexed in Scilit:
- Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesJournal of Hematology & Oncology, 2016
- Targeting Isocitrate Dehydrogenase (IDH) in Cancer2016
- Molecular Pathways: Isocitrate Dehydrogenase Mutations in CancerClinical Cancer Research, 2016
- New IDH1 mutant inhibitors for treatment of acute myeloid leukemiaNature Chemical Biology, 2015
- Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoACS Medicinal Chemistry Letters, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsJournal of Experimental Medicine, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009